1. ALLA AKTIER
  2. NYHETER
  3. 2CUREX

2cureX

Nyheter 2cureX Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Improved communication from 2cureX AB

Moving forward we will continuously inform our respected shareholders about matters of importance. We have humbly understood that there is much needed room for improvement and we aim to deliver clear and transparent communication.

In the updated owner list it could be interpreted that Ole Thastrup has sold shares which he has not. For the purpose of clarity we hereby inform our shareholders that the discrepancy in Mr Thastrup’s share count is solely connected to borrowed shares to our market maker Mangold Fondkommission for the benefit of our shareholders. Mr Thastrup has not sold a single share to date and remains very confident in the company’s future.

For more information about 2cureX:

Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346

About 2cureX

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
                •  IndiTreat® Start (first-line therapy)
                •  IndiTreat® Extend & Explore (third-line options)
 
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
 
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.

Attachments

Improved communication from 2cureX AB

Datum 2025-07-11, kl 21:10
Källa MFN
Bifogade filer
Improved communication from 2cureX AB